Clinical trials: Alopecia Areata
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Alopecia Areata
Litfulo Capsules Special Investigation
The objective of this Study is to confirm the safety during the long-term use of this drug and the effectiveness during the use of this drug under the actual use in the patients treated with this drug.
- Trial name
- NCT06279221
- Testing
- LITFULO
- Where
- Japan
- Volunteers
- 664 people
- Sponsor
- Pfizer
Alopecia Areata
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
- Trial name
- NCT07749716
- Testing
- Drug: VC005 tablets, VC005 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Severe Alopecia Areata
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss.
- Trial name
- B7981027 (NCT07029711)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 83 sites in United States, China and 7 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Alopecia Areata
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers.
- Trial name
- NCT06562270
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorEvitas
Microneedling-Assisted Delivery, Cetirizine
Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Areata
This study planned to measure the effectiveness and safety of microneedling aided administration of cetirizine 1% versus latanoprost 0.01% in alopecia areata.
- Conditions
- Microneedling-Assisted Delivery, Cetirizine, Latanoprost, Alopecia Areata
- Trial name
- NCT07757867
- Testing
- Cetirizine (Zyrtec), Latanoprost, Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tanta University
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in…
- Trial name
- NCT06444451
- Testing
- Amlitelimab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 166 people
- Sponsor
- Sanofi
Alopecia Areata
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders.
- Trial name
- NCT07226531
- Testing
- Ritlecitinib
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Pfizer
Alopecia Areata
Intralesional Cyclosporine for Alopecia Areata
Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring, focal areas of hair loss. Due to its resulting disfigurement and unpredictable course, it is recognized as a serious medical condition with severe…
- Trial name
- NCT07029204
- Testing
- CycloSPORINE Injectable Product, Saline Solution
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, Davis
Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body.
- Trial name
- Jump Up AA JP (NCT07023302)
- Testing
- Upadacitinib
- Where
- 15 sites in Japan
- Volunteers
- 125 people
- Sponsor
- AbbVie
Alopecia Areata(AA), Alopecia Areata
Serum Ferroptosis Biomarkers (GPX4, MDA) in Alopecia Areata
This study aims to investigate the potential role of the ferroptosis pathway in the pathogenesis and clinical course of Alopecia Areata (AA).
- Conditions
- Alopecia Areata(AA), Alopecia Areata, Alopecia Areata (& Ophiasis), Alopecia
- Trial name
- NCT07733063
- Where
- Turkey (Türkiye)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Istanbul Training and Research Hospital
Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA)
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
The purpose of this trial is to measure safety and tolerability of subcutaneous (SC) VIS171 in combination with standard of care in participants with autoimmune disease(s).
- Conditions
- Systemic Lupus Erythematosus (SLE), Alopecia Areata (AA), Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT06799520
- Testing
- VIS171
- Where
- 6 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alopecia Areata Depression, Depression
Prevalence of Depression Among Patients With Alopecia Areata
This study aims to assess how common depression is among patients with alopecia areata at Sohag University Hospital using a questionnaire. It is an observational study with no treatment involved.
- Trial name
- AA_DEP (NCT07711574)
- Testing
- Observation only
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Alopecia Areata, Fecal Microbiota Transplantation (FMT)
The Role of Gut and Skin Microbiota in Alopecia Areata
The goal of this clinical trial is to learn if fecal microbiota transplantation (FMT) works to treat alopecia areata in adults. It will also learn about the safety of FMT.
- Conditions
- Alopecia Areata, Fecal Microbiota Transplantation (FMT), T Cell Subsets, Microbiome
- Trial name
- RGSM-AA-ICS (NCT07705217)
- Testing
- Fecal Microbial Transplant Enema
- Where
- Croatia
- Volunteers
- 30 people
- Sponsor
- Polyclinic GrandMed
Alopecia Areata
New Topical Treatment in Patchy Alopecia Areata
Alopecia areata (AA) is a chronic immune disease characterized by non-scarring hair loss of the scalp or other hair-bearing areas Patients with AA frequently report high levels of dissatisfaction with commonly used treatment…
- Trial name
- NCT07696585
- Testing
- topical metformin 30% ointment, Topical Simvastatin 2% ointment, Topical betamethasone valerate 0.1% ointment
- Volunteers
- 60 people
- Sponsor
- Sohag University
Alopecia Areata, Vitiligo
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
- Trial name
- NCT06602232
- Testing
- DR-01
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Dren Bio
Alopecia Areata, Alopecia Totalis
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06747611
- Testing
- Vancomycin, Neomycin and MTT capsules
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Vitiligo, Psoriasis
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders
- Conditions
- Vitiligo, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Trial name
- INFLAMMAVit (NCT03976622)
- Testing
- Blood samples, Skin biopsies
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Bordeaux
Alopecia Areata
Regeneron AA Multicenter (Dupilumab)
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the…
- Trial name
- NCT05551793
- Testing
- Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Emma Guttman